Evidence map›Paper›PMID 36044386›Full record

ArticleBlood advances2023

Impact of mesenchymal stromal cell-derived vesicular cargo on B-cell acute lymphoblastic leukemia progression.

Christina Karantanou, Valentina R Minciacchi, Rahul Kumar, Costanza Zanetti, Jimena Bravo, Raquel S Pereira, Georg Tascher, Tobias Tertel, Adriana Covarrubias-Pinto, Katrin Bankov and 8 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Syndecans in hematopoietic cells and their niches.American journal of physiology. Cell physiology · 2024
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Christina KarantanouInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.ORCID 0000-0002-2161-914X
Valentina R MinciacchiInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.ORCID 0000-0002-9296-9403
Rahul KumarInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.
Costanza ZanettiInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.ORCID 0000-0001-9384-1543
Jimena BravoInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.
Raquel S PereiraInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.
Georg TascherInstitute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-5907-3947
Tobias TertelInstitute for Transfusion Medicine, University Hospital Essen, Essen, Germany.ORCID 0000-0001-8659-8610
Adriana Covarrubias-PintoInstitute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-8946-2804
Katrin BankovDepartment of Pathology, Goethe University, Frankfurt am Main, Germany.
Lisa-Marie PfeffermannGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
Halvard BonigGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.ORCID 0000-0003-0088-2675
Paola Divieti-PajevicGoldman School of Dental Medicine, Boston University, Boston, MA.
David G McEwanCancer Research UK Beatson Institute, Glasgow, United Kingdom.ORCID 0000-0003-0353-6532
Bernd GiebelInstitute for Transfusion Medicine, University Hospital Essen, Essen, Germany.ORCID 0000-0003-2446-948X
Christian MünchInstitute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.
Ivan DikicInstitute of Biochemistry II, Medical Faculty, Goethe University, Frankfurt am Main, Germany.
Daniela S KrauseInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.ORCID 0000-0003-3603-1119
Goethe University Frankfurt · DEGeorg Speyer Haus · DEEssen University Hospital · DEBoston University · USCancer Research UK Scotland Institute · GBGerman Red Cross · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukemia cells reciprocally interact with their surrounding bone marrow microenvironment (BMM), rendering it hospitable to leukemia cell survival, for instance through the release of small extracellular vesicles (sEVs). In contrast, we show here that BMM deficiency of pleckstrin homology domain family M member 1 (PLEKHM1), which serves as a hub between fusion and secretion of intracellular vesicles and is important for vesicular secretion in osteoclasts, accelerates murine BCR-ABL1+ B-cell acute lymphoblastic leukemia (B-ALL) via regulation of the cargo of sEVs released by BMM-derived mesenchymal stromal cells (MSCs). PLEKHM1-deficient MSCs and their sEVs carry increased amounts of syntenin and syndecan-1, resulting in a more immature B-cell phenotype and an increased number/function of leukemia-initiating cells (LICs) via focal adhesion kinase and AKT signaling in B-ALL cells. Ex vivo pretreatment of LICs with sEVs derived from PLEKHM1-deficient MSCs led to a strong trend toward acceleration of murine and human BCR-ABL1+ B-ALL. In turn, inflammatory mediators such as recombinant or B-ALL cell-derived tumor necrosis factor α or interleukin-1β condition murine and human MSCs in vitro, decreasing PLEKHM1, while increasing syntenin and syndecan-1 in MSCs, thereby perpetuating the sEV-associated circuit. Consistently, human trephine biopsies of patients with B-ALL showed a reduced percentage of PLEKHM1+ MSCs. In summary, our data reveal an important role of BMM-derived sEVs for driving specifically BCR-ABL1+ B-ALL, possibly contributing to its worse prognosis compared with BCR-ABL1- B-ALL, and suggest that secretion of inflammatory cytokines by cancer cells in general may similarly modulate the tumor microenvironment.

Indexed as

Burkitt LymphomaMesenchymal Stem CellsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAnimalsCell CommunicationHumansMiceSyndecan-1SynteninsTumor MicroenvironmentSyndecan-1Syntenins

Identifiers

PMID36044386
PMCPMC10111361
OpenAlexW4293786848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.